A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by activating the mother’s immune system to produce defence proteins, which are then passed to the foetus through the placenta. This maternal immunity offers newborns with immediate protection from the point of delivery, exactly when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still provide substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine at the recommended time, whilst observing that protection can still occur even if given later in the third trimester.
- Nearly 85% protection when vaccinated 4 weeks before birth
- Antibodies from the mother transferred through placenta protect newborns from day one
- Protection possible with 2-week gap before premature birth
- Vaccination during the third trimester still provides significant infant protection
Compelling evidence from current research
The performance of the pregnancy RSV vaccine has been established through a extensive research programme carried out throughout England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately 90 per cent of all births during that six-month timeframe, providing strong and reliable evidence of the vaccine’s actual performance. The study’s findings have been validated by the UK Health Security Agency as showing robust protection for newborns during their most vulnerable early months. The breadth of this investigation gives healthcare professionals and prospective parents with trust in the vaccine’s established performance across varied populations and settings.
The results present a compelling picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV during the study period, with the vast majority being infants whose mothers had not been given the vaccination. This stark contrast underscores the vaccine’s essential role in preventing serious illness in newborns. The decrease in hospital admissions exceeding 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms associated with severe RSV infection. These findings reinforce the importance of the vaccination programme introduced in the UK in 2024.
Study design and parameters
The research analysed birth and hospital admission records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospital admissions. The substantial sample size and thorough nature of the data gathering ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or limited subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology measured practical outcomes rather than laboratory-based settings, providing tangible evidence of how the vaccine performs when administered across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the hazards
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.
The infection triggers inflammation deep within the lungs and airways, making it dangerously difficult for vulnerable newborns to breathe and feed effectively. Parents commonly see their babies visibly struggling, their chests rising whilst they attempt to draw sufficient oxygen into their damaged lungs. Whilst most newborns improve through palliative treatment, a limited though important proportion perish from RSV-related complications annually, making immunisation programmes a vital health service objective for safeguarding the youngest and most at-risk people in our communities.
- RSV triggers lung inflammation, leading to severe breathing difficulties in babies
- Approximately half of infants contract the virus during their first few months alive
- Symptoms span from minor cold-like symptoms to life-threatening chest infections needing hospital treatment
- More than 20,000 UK babies require serious hospital care for RSV annually
- Small numbers of infants die from RSV related complications each year in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have emphasised the significance of pregnant women getting their jab at the ideal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that timing is crucial for guaranteeing newborns receive the most robust immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery provides approximately 85% protection, experts encourage women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies passed to their babies through the placenta.
The messaging from public health bodies remains clear: pregnant women should prioritise getting vaccinated during their final three months, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured expectant mothers that protection is still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach acknowledges the realities of pregnancy and childbirth whilst ensuring strong protection for at-risk infants during their earliest and most vulnerable period when RSV represents the highest danger of severe infection.
Regional variations in vaccine uptake
Whilst the RSV vaccine programme has been launched across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Some areas have attained higher vaccination coverage among eligible pregnant women, whilst others remain focused to increase awareness and access to the jab. These geographical variations reflect differences across healthcare infrastructure, communication strategies, and community involvement initiatives, though the national data shows consistently strong protection regardless of geographical location.
- NHS trusts launching multiple messaging strategies to engage with pregnant women
- Inconsistencies across regions in immunisation take-up throughout England require targeted improvement
- Regional health providers tailoring initiatives to align with specific population needs
Practical implications and parent viewpoints
The vaccine’s remarkable effectiveness translates into real advantages for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the rollout of this protective measure, the 80% decrease in admissions means thousands of infants protected against serious illness. Parents no more face the troubling prospect of seeing their babies struggle for breath or labour to feed, symptoms that define severe RSV infections. The vaccine has fundamentally shifted the terrain of neonatal lung health, offering expectant mothers a active means to safeguard their most vulnerable children during those critical early months.
For families like that of Malachi, whose severe RSV infection led to devastating brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s support of the jab highlights the transformative consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to pregnant women in their late pregnancy, transforming what was once an predictable seasonal threat into a controllable health concern.